As an established biopharmaceutical company prepared for the global launch of a new rare blood cancer therapy, it sought to strengthen awareness of its leadership in the disease area while building meaningful connections with key stakeholders. The company recognized a unique opportunity to engage patient advocacy organizations, healthcare professionals, researchers, industry leaders, media, and internal teams ahead of launch through educational programming at major oncology conferences, including ASCO, ASH, AACR, and EHA.
The goal was not simply to promote an upcoming therapy, but to establish credibility, elevate important disease-state discussions, and create lasting visibility among audiences likely to influence awareness, adoption, and engagement following launch.
PAS collaborated with the company’s Patient Advocacy and Public Relations teams to develop and execute a series of disease awareness programs designed to engage a broad audience while differentiating the company from other organizations participating in the same scientific meetings.
Together, the teams identified high-interest discussion topics, recruited respected speakers and moderators, coordinated event logistics, and developed promotion strategies that would maximize attendance and engagement. Programs focused on timely and relevant topics including global patient advocacy infrastructure, diversity in cancer clinical trials, and the role of patient storytelling in advancing healthcare innovation.
To further expand visibility and encourage broader industry discussion, PAS helped ensure participation from patient advocates, clinical experts, industry stakeholders, and media representatives. Prominent healthcare journalists and editors were engaged to moderate discussions, helping create compelling conversations that resonated beyond the conference venue itself.
Each event attracted a diverse audience of more than 200 attendees, including representatives from patient advocacy organizations, industry research and development teams, healthcare professionals, media, and company leadership. The programs also generated media interest and industry coverage that extended the reach of conversations beyond the conferences themselves.
By creating highly visible educational forums and facilitating meaningful stakeholder engagement, PAS helped strengthen the company’s position as a recognized leader in oncology and a trusted contributor to important conversations shaping the future of cancer care. The initiative increased awareness of the upcoming product launch, enhanced credibility among key stakeholder groups, and reinforced the company’s commitment to partnering with the patient and healthcare communities.
Category:
